Spire Healthcare’s FY24 results show the group met many of the guidance measures, despite a changing market. However the share price dropped by 15%.
Secondary careSpire Healthcare’s FY24 results show the group met many of the guidance measures, despite a changing market. However the share price dropped by 15%.
Secondary careHealthInvestor understands a deal for UK cancer care business Genesis Care is in the documentation stage. The group denies it.
M&ASources suggest Community Health and Eyecare will be sold later this year.
M&A